Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stillman's Skin Bleach Cream is a topical skin-lightening product originally developed by The Stillman Company. Historically, its primary active ingredient was ammoniated mercury, a compound that functions by inhibiting the enzyme tyrosinase, which is the rate-limiting step in the biosynthesis of melanin. By reducing melanin production, the cream was marketed to treat freckles, dark spots, and general skin hyperpigmentation. However, due to the systemic toxicity of mercury—which can lead to renal damage, neurological impairment, and skin irritation—the use of mercury in cosmetic products has been banned or severely restricted by the U.S. Food and Drug Administration (FDA) and other global health authorities. While modern versions of the brand exist in certain international markets, the product is most significant in a clinical context for its historical association with mercury-based depigmentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stillman's Skin Bleach Cream.